Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: BRAVEHEART who wrote (18)	1/16/1999 12:57:00 PM
From: yosi s	Read Replies (1) \| Respond to of 423

"Memantine has a 10 year treatment history for dementia in Europe. " I am unaware that Dementia is cured or improved upon in any significant way in Europe. So 10 years of history, may show its side effect profile, but failed to show efficacy....

To: BRAVEHEART who wrote (18)	1/16/1999 1:04:00 PM
From: yosi s	Read Replies (1) \| Respond to of 423

"I believe those which offer the highest degree of success with this approach are products which are already approved for other indications" You missed amgen epogen neupogen . As well as any significant breakthrough. After all enlarge indication to an approved product increases market penetration. though off label useage has to be taken into account. I think that a more efficacious method. is to look at a product. see its mechanisme of action, and have significant proof that it mechanisme of action works as the model supposes. and obsereve closely its safety profile. ie look at history of Tagamet H 2 blocker. the first H2 blocker failed due to saeft issue . yet the mechanisme works, with So once a product with the same mechanisme came on with a safety profile. you had a blockbuster drug. And a family of me too ...